GeoVax Labs is a biotechnology business based in the US. GeoVax Labs shares (GOVX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.01 – an increase of 3.4% over the previous week. GeoVax Labs employs 17 staff and has a trailing 12-month revenue of around $4 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.01 |
|---|---|
| 52-week range | $0.73 - $11.18 |
| 50-day moving average | $1.25 |
| 200-day moving average | $2.30 |
| Wall St. target price | $10.70 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-4.82 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.9893 from 2025-05-01
| 1 week (2025-04-25) | 1.28% |
|---|---|
| 1 month (2025-04-04) | -3.01% |
| 3 months (2025-02-04) | -43.14% |
| 6 months (2024-11-04) | -44.73% |
| 1 year (2024-05-03) | -38.55% |
|---|---|
| 2 years (2023-05-04) | -89.85% |
| 3 years (2022-05-04) | 11.55 |
| 5 years (2020-05-04) | 165.06 |
| Revenue TTM | $4 million |
|---|---|
| Gross profit TTM | $-19,759,026 |
| Return on assets TTM | -180.23% |
| Return on equity TTM | -462.31% |
| Profit margin | 0% |
| Book value | $0.48 |
| Market Capitalization | $14 million |
TTM: trailing 12 months
We're not expecting GeoVax Labs to pay a dividend over the next 12 months.
You may also wish to consider:
GeoVax Labs's shares were split on a 1:15 basis on 30 January 2024 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your GeoVax Labs shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for GeoVax Labs shares which in turn could have impacted GeoVax Labs's share price.
Over the last 12 months, GeoVax Labs's shares have ranged in value from as little as $0.73 up to $11.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GeoVax Labs's is 3.707. This would suggest that GeoVax Labs's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put GeoVax Labs's beta into context you can compare it against those of similar companies.
GeoVax Labs, Inc. , a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U. S.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .